Cancer Clinical Trial
A Pilot Study on the Implementation of the WLS-Cancer Care Protocol
|Contact||Cristina C Hendrix, DNS, GNP-BC, FAAN|
|Start date||May 3, 2017|
|Completion date||September 30, 2017|
The purpose of the pilot is to test the feasibility of developing and implementing the Williams LifeSkills Cancer Care (WLSCC) and examining its preliminary impact on caregiver well-being and patient well-being. The study is a two-arm randomized intervention pilot (WLSCC vs. Usual Care [UC]) with data collection at baseline, immediately after training, and 2 weeks after completing the training. Study setting is at the breast and thoracic cancer clinics at the Duke Cancer Clinic. A total of 40 cancer patients (20 breast cancer patients and 20 lung cancer patients) and their caregivers (for a total N of 80) will be recruited for the pilot. The WLSCC will involve six 30-minute phone sessions and will encompass the application of 10 psychosocial skills within the context of cancer caregiving. Descriptive statistics will be used to detail recruitment/retention rate, fidelity rate, and the baseline demographic and clinical characteristics for the total sample and each group. Plots of the individual trajectories (within-person scores over time) will be used to identify the pattern(s) of change over time, and assess between-person variability in baseline values (intercepts) and trajectories (slopes). This study carries minimal risk to study participation.
The pilot's specific aims are to:
1. Test the feasibility of (a) recruiting lung and breast cancer patients and their caregivers (hereafter, "dyads) at the Duke Cancer Center (DCC) outpatient clinic; (b) training interventionists to deliver the WLSCC protocol; (c) delivering the WLSCC protocol by phone.
2. Examine the immediate and two-week impact of the WLSCC on caregiver quality of life, anxiety and depression, caregiving preparedness, and social support as well as patient's well-being (Functional Assessment of Cancer Therapy.
Design and Procedures The pilot is two-arm randomized intervention pilot (WLSCC vs. Usual Care [UC]) with data collection at baseline (T1), immediately after training (T2), and 2 weeks after completing the training (T3). Caregivers will have an option to receive the WLCCC protocol, should they wish, after the data collection period. A stratified randomization will be conducted with stratifying variable being type of cancer and the block size will be 2.
The pilot setting is at the breast and thoracic cancer clinics at the DCC, Durham, NC. The WLSCC will involve approximately six 30-minute phone sessions between the caregiver and interventionist. The six calls will be delivered within three weeks of consent and will use intervention scripts for standardization of delivery.
The training will use the WLS format to assess issues and discuss strategies for cancer care including caregiver stress management. The context of discussion will be tailored by using the cancer issues endorsed by the cancer patient at baseline data collection. In delivering the interactive WLSCC training, the interventionist will preface each session by stating that the protocol is designed to enable them to cope more effectively with demanding caregiving situations and stressful life situations, to improve their relationships with others, and to increase the proportion of positive thoughts and feelings in their daily lives. The interventionist will frequently prompt the caregiver to raise questions that pertain to their situation (using cancer symptoms endorsed by cancer patient at baseline survey). At the end of each telephone session, the interventionist will request for the caregiver to complete log entries to provide an opportunity to reflect or put into action the WLSCC psychosocial skills taught in each session.
Subject Recruitment & Compensation:
The study team will review every week the list of adult patients who are scheduled for an outpatient visit at DCC Breast Cancer Clinic and Thoracic Clinic. For those who initially meet the criteria of aged 18 years and above and with primary breast or thoracic cancer diagnosed less than a year of the scheduled visit, the team will send an invite letter by mail to describe the study and invite their participation. A number will be provided that the patient or caregiver can call to decline participation. If no phone call or voice message is received on the opt-out number after 2 weeks of mailing the letter, the study staff will make plans to approach patient and family/friend during the visit to determine further eligibility for participation.
The study staff will visit the Duke Breast and Thoracic cancer clinic at least three times a week. She/he will approach patients who have not opted out of the study to determine if the family/friend accompanying the patient meets the definition of a caregiver for this study. If yes, the study staff will explain the study including the possibility that the dyad maybe assigned to either the WLSCC or UC group. If a working telephone number is assured and the dyads show interest in study participation, consent will be obtained from the dyad. After consent is obtained, baseline data (T1) for measures will be obtained. Using a laptop, the study staff will access study database and measures using the secure Duke server. He/she will ask questions in the baseline measures and responses will be directly entered to the study database. Thereafter, the study staff will assign the dyad a number that is randomly determined by a computer program. Each number from 1-40 will be assigned as either WLSCC or UC. The interventionist will call the caregiver at the scheduled first session. Before the first call ends, schedules for calls 2 to 6 will be established with the caregiver.
All follow-up data will be collected by phone. Follow-up data collection for T2 will be on the date of the last phone call for the WLSCC group and 3 weeks after consent was obtained in the UC group. T3 data will be collected two weeks after T2 data were collected in the WLSCC group and five weeks after consent in the UC group.
Data Analysis & Statistical Considerations:
Descriptive statistics will be used to detail recruitment/retention rate, fidelity rate, and the baseline demographic and clinical characteristics for the total sample and each group. For each caregiver and patient outcome measure, descriptive statistics will be calculated at baseline and at each follow-up. Plots of the individual trajectories (within-person scores over time) will be used to identify the pattern(s) of change over time, and assess between-person variability in baseline values (intercepts) and trajectories (slopes).Hierarchical mixed-effects models will be used to delineate and summarize trends and relationships in the data while nesting for dyads. This pilot study will focus on estimating effective size for WLSCC rather than statistical significance testing dues to the exploratory nature of the pilot study. When statistical testing is conducted, non-directional tests will be performed with level of significance set at 0.10.
|Recruiting||NCT01285037 - A Study of LY2801653 in Advanced Cancer||Phase 1|
|Active, not recruiting||NCT00680992 - Study of Denosumab in Subjects With Giant Cell Tumor of Bone||Phase 2|
|Completed||NCT00340522 - Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development||N/A|
|Terminated||NCT01441115 - ECI301 and Radiation for Advanced or Metastatic Cancer||Phase 1|
|Completed||NCT01077414 - Phenomenological Study of Psycho-Socio-Spiritual Healing in the Context of Chronic or Life-Threatening Illness||N/A|
|Active, not recruiting||NCT00587886 - Estrogen, Diet, Genetics and Endometrial Cancer||N/A|
|Enrolling by invitation||NCT02565004 - Clinical and Laboratory Analysis of Familial Cancer||N/A|
|Recruiting||NCT02921919 - Open-Label Extension and Safety Study of Talazoparib||Phase 2|
|Recruiting||NCT02891993 - Pilot Study of a Symptom Monitoring Intervention for Hospitalized Patients With Cancer||N/A|
|Recruiting||NCT02839889 - Tolerability, Safety, and Feasibility of Naloxegol in Patients With Cancer and OIC (Opioid Induced Constipation)||Phase 4|
|Recruiting||NCT02869802 - Prospectively Defining Metastatic Pancreatic Ductal Adenocarcinoma Subtypes by Comprehensive Genomic Analysis||N/A|
|Not yet recruiting||NCT02883699 - Individually Tailored Training Prescriptions in Cancer Patients: The TOP Study||N/A|
|Recruiting||NCT02502396 - Rivaroxaban Utilization for Treatment and Prevention of Thromboembolism in Cancer Patients: Experience at a Comprehensive Cancer Center||N/A|
|Recruiting||NCT02552953 - A Pharmacologic Study of CYC065, a Cyclin Dependent Kinase Inhibitor, in Patients With Advanced Cancers||Phase 1|
|Recruiting||NCT02550925 - Acceptance and Commitment Therapy (ACT) for Anxious Cancer Survivors||N/A|
|Recruiting||NCT02866851 - Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy||N/A|
|Recruiting||NCT02758639 - Wonders & Worries: A Clinical Trial of a Psychosocial Intervention for Children Who Have a Parent With Cancer||N/A|
|Recruiting||NCT02765451 - Study Evaluating Intervention in the Development of Clinical Research in Non-Academic Health Institution (ERNU)||N/A|
|Recruiting||NCT02483247 - A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer||Phase 1/Phase 2|
|Recruiting||NCT02528357 - GSK3174998 Alone or With Pembrolizumab in Subjects With Advanced Solid Tumors (ENGAGE-1)||Phase 1|